Australia
AirCar developer signs groundbreaking manufacturing deal
KleinVision a.s., the Slovakia-based developer of the world's first certified flying car, the AirCar, has made a groundbreaking move towards realizing the dreams of individuals seeking to navigate through traffic congestion by taking to the skies in their cars NITRA, Slovakia, March 27, 2024 /PR...
White Cliff (ASX:WCN) unfurls historic high-grade uranium-copper from Northwest Territories
PERTH, Australia, March 26, 2024 /PRNewswire/ -- White Cliff Minerals dataset digitisation efforts have unearthed multiple high-grade uranium and copper targets in the northern half of its large-scale Radium Point exploration project inCanada's Northwest Territories. The older historical dataset...
Compute for Climate Fellowship Announces Inaugural Winners and Opens Applications for 2024
The program funds proof of concepts for new ideas leveraging advanced cloud computing, including generative AI and high-performance computing, to solve some of the biggest challenges in the fight against climate change LJUBLJANA, Slovenia, March 21, 2024 /PRNewswire/ -- The International Researc...
Enfinity Global completes a minority sale of its 400 MW operating portfolio in the United States to Kyushu Electric
MIAMI, March 19, 2024 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today announced the successful completion of a minority sale in its 400 MW U.S. operating portfolio to Kyushu Electric Power Co. Inc. (Kyushu Electric), a leading Japanese utility. Kyushu Electric has now a ...
REC Wins Best Solar Panels and Best After-Sales Support in 2024 for the 2nd Year in a Row
MELBOURNE, Australia, March 15, 2024 /PRNewswire/ -- REC Group
Pulsenmore is expanding the application of its home ultrasound solution for pregnant women: a clinical trial with Michigan Medicine will focus on the remote assessment of the fetal biophysical profile
RAMAT GAN, Israel, March 13, 2024 /PRNewswire/ -- Pulsenmore (TASE:PULS), the world leader in self-scan ultrasound technology for at-home use and remote clinical diagnosis, announces its new clinical study collaboration with Michigan Medicine. The study will examine the ability to conduct a remot...
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). * In trial participants where standard of care (SOC) imagin...
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Highlights: * Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® * Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R * Confirmation that m...
NIGO DESIGNS FIRST PENFOLDS GRANGE LIMITED-EDITION
An icon re-imagined. First-ever design takeover by cultural pioneer and Human Made Creative Director. ADELAIDE, Australia, Feb. 23, 2024 /PRNewswire/ -- Today Penfolds unveiled a new collaboration for Penfolds flagship wine, Grange. TheGrange by NIGO release celebrates the first-ever design take...
The Kingdom of Saudi Arabia unveils Zarqa Al Yamama - the inaugural Arabic Grand Opera
LONDON, Feb. 21, 2024 /PRNewswire/ -- Zarqa Al Yamama, the first Grand Opera produced by The Saudi Theater and Performing Arts Commission, one of the 11 sector specific commissions under the Ministry of Culture, was internationally unveiled at an exclusive event inLondon's historic Goldsmiths' Ha...
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...
Style3D Research Shines the Show with additional Two Papers Accepted at SIGGRAPH ASIA 2023 on Cloth Simulation Innovations
SYDNEY, Jan. 10, 2024 /PRNewswire/ -- The electrifying stage of SIGGRAPH Asia 2023 witnessed Style3D Research's triumphant unveiling of two groundbreaking research papers through captivating oral presentations. This pinnacle gathering, renowned as a global hub for computer graphics, provided the ...
Seeing Machines unveils latest Guardian technology at CES 2024
- Guardian is the company's world-leading Aftermarket Driver Monitoring System for commercial vehicles and is currently connected to 54,000 vehicles globally - The new version includes Drowsiness Detection with refined microsleep detection and eye-gaze tracking to protect drivers fro...
Canadian Solar's e-STORAGE to Deliver 220 MWh DC of Battery Storage Solutions to Epic Energy's Mannum Project in South Australia
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc
Recurrent Energy Completes Sale of 100 MW/200 MWh Battery Energy Storage Project in South Australia to Epic Energy
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc.
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN
ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...
Following a digital Rebrand, Little Black Book Looks Back at a Decade of Exponential Growth and Record Turnover
* LBB reports continued growth in business in the UK and an acceleration in growth internationally with increased business in theUSA, Canada, Australia, India and Germany. * A record turnover for the business of £3.2m in 2022, with a turnover of around £4m forecast in 2023. * The world's le...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 247 media titles]
2024-03-28 14:27